Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | ASPH | Q12797 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.33 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.33 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395367 | 1.00 | PIK3R1 (0.36) | PIK3R1PIK3CAASPHPIK3CDKCNQ3 | |
| SCHEMBL3840400 | 0.80 | PIK3R1 (0.42) | PIK3R1PIK3CAASPHPIK3CDKCNQ3 | |
| SCHEMBL30488644 | 0.78 | ASPH (0.36) | ASPHULK1CFTR | |
| SCHEMBL30433748 | 0.78 | PIK3R1 (0.38) | PIK3R1PIK3CAASPHPIK3CDKCNQ3 | |
| SCHEMBL1471015 | 0.78 | PIK3R1 (0.38) | PIK3R1PIK3CAASPHPIK3CDKCNQ3 | |
| SCHEMBL11919268 | 0.78 | ASPH (0.36) | ASPHULK1CFTR | |
| SCHEMBL16656835 | 0.75 | HPGD (0.35) | ASPHLRRK2CYP1A2ULK1CFTR | |
| SCHEMBL31214077 | 0.75 | PIK3CD (0.41) | PIK3R1PIK3CAASPHPIK3CDCFTR | |
| SCHEMBL28682675 | 0.75 | ASPH (0.34) | ASPHPIK3CDCYP11B1CYP11B2ULK1 | |
| SCHEMBL1440021 | 0.75 | PIK3CD (0.41) | PIK3R1PIK3CAASPHPIK3CDCFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111995587-A | 1, 4-disubstituted 3, 4-dihydro-2 (3H) -quinazolinone compound and synthetic method and application thereof | 上海工程技术大学 | 2020-11-27 | — | — | CN | claimed |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260070937-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705298-A2 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | MOMA THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042750-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12497419-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-12479833-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115369-A2 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | disclosed |
| CN-1910173-A | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PIK3R1 385/4885PIK3CA 35/4885ASPH 3346/4885 |
| US-20260138991-A1 | SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES | POLA1, SUB1, CTDSP1 | PIK3R1 1381/4885PIK3CA 1206/4885ASPH 985/4885 |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | PIK3R1 906/4885PIK3CA 434/4885ASPH 2239/4885 |
| US-12559508-B2 | Semi-saturated bicyclic derivatives and related uses | POLA1, CTDSP1, SUB1 | PIK3R1 839/4885PIK3CA 774/4885ASPH 846/4885 |
| US-12479833-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | PIK3R1 355/4885PIK3CA 177/4885ASPH 1460/4885 |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | PIK3R1 158/4885PIK3CA 152/4885ASPH 3102/4885 |
| US-20260042750-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, ATG7, SQSTM1 | PIK3R1 145/4885PIK3CA 163/4885ASPH 3139/4885 |
| US-20260070937-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, GLRA1, GLRB | PIK3R1 1561/4885PIK3CA 4638/4885ASPH 4097/4885 |
| US-12497419-B2 | Organic electroluminescent materials and devices | L1CAM, CHRM1, SSB | PIK3R1 4769/4885PIK3CA 4807/4885ASPH 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.